Evonik's Strategic Divestment Plan Sparks Analyst Reevaluation

Evonik's sale of Syneqt and Oxeno divisions aims to unlock hidden value. Key investor events include Q1 2026 results, AGM, and a new CFO appointment.

A significant portfolio restructuring at German specialty chemicals group Evonik is drawing close scrutiny from market analysts. The company's proposed sale of its Syneqt and Oxeno divisions is seen as a move that could unlock substantial hidden value currently obscured by its conglomerate structure. This strategic shift provides concrete grounds for a potential re-rating of the stock, which has already rallied 12% since the end of March.

Upcoming Milestones for Investor Focus

The immediate roadmap for investors is now centered on several key dates. The company will release its Q1 2026 quarterly figures on 8 May 2026, which must demonstrate whether recent strategic initiatives are taking hold and support the full-year EBITDA forecast of €1.7 to €2.0 billion. This will be followed by a virtual Annual General Meeting in Essen on 3 June 2026. The agenda for that meeting includes a vote on a proposed dividend of €1.00 per share and the crucial appointment of a new Chief Financial Officer, a role that has been vacant since last September. This personnel decision is expected to significantly shape the firm's future capital allocation strategy.

Unlocking Value in Non-Core Assets

With no acquisition plans until 2027, Evonik's management is squarely focused on debt reduction and shedding non-core operations. The Syneqt unit, which bundles infrastructure services at the Marl and Wesseling sites, is a particularly attractive asset, generating an annual EBITDA of approximately €200 million. Analysts at British bank Barclays note that recent comparable infrastructure deals in the sector have been valued at around nine times EBITDA. A sale could therefore command a significantly higher multiple than the market currently awards the entire conglomerate. Consequently, Barclays maintains its "Overweight" rating on Evonik shares with a price target of €17, while also raising its own 2026 EBITDA estimate to €1.89 billion.

Navigating Trade Policy for Potential Gain

Beyond the portfolio overhaul, the company is steering through a complex trade policy landscape. Recent US tariffs triggered profit-taking across the chemical sector at the start of the week. Interim CFO Claus Rettig acknowledged provisions in the low double-digit million-euro range due to the tense situation. However, CEO Christian Kullmann views the long-term implications as a potential strategic advantage. Given that Evonik produces roughly 80% of the products it sells in the United States locally, new tariffs could disadvantage Chinese competitors and allow Evonik to capture additional market share.

Concurrently, an internal cost-saving program is progressing. The plan aims to reduce costs by €400 million and cut 2,000 positions by the end of 2026. Capital freed up by this efficiency drive, along with a new dividend policy set to begin in 2026, will be directed toward further debt reduction and investments in Asian growth markets.